Nedenfor (i tabel 1) nævnes de formodede bivirkninger, inddelt i systemorganklasse og frekvens, som oftere blev rapporteret (> 0, 2% og difference > 1 patient) hos de patienter, der blev behandlet med sitagliptin end hos de patienter, der fik placebo.
Adverse reactions considered as drug-related reported in patients treated with sitagliptin occurring in excess (> 0.2% and difference > 1 patient) of that in patients treated with placebo are listed below (Table 1) by system organ class and frequency.